{
    "clinical_study": {
        "@rank": "166639", 
        "acronym": "VEST", 
        "arm_group": {
            "arm_group_label": "Patients with residual OAB symptoms", 
            "description": "Urge urinary incontinence, urgency, and frequency after treatment with other antimuscarinics"
        }, 
        "brief_summary": {
            "textblock": "This is a 12 month non-interventional study with solifenacin succinate, evaluating the\n      effect of solifenacin on quality of life (QoL) of patients previously treated with\n      antimuscarinics (Males and Females with Overactive Bladder (OAB) symptoms withdrawing their\n      treatment with antimuscarinics because of safety and/or efficacy reasons) - measured by\n      Perception of Treatment Satisfaction (TS-VAS) and to evaluate the effect of solifenacin on\n      quality of life measured by Over Active Bladder-q Short Form (OAB-q SF), EuroQol Group\n      scoring system (EQ-5D-5L)."
        }, 
        "brief_title": "A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Urinary Bladder, Overactive", 
        "condition_browse": {
            "mesh_term": "Urinary Bladder, Overactive"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient willing and able to complete the questionnaires\n\n          -  Diagnosis of OAB\n\n          -  Previous unsuccessful OAB medication (antimuscarinic treatment for at least 1 month)\n             less than 4 weeks ago defined by:\n\n               -  number of micturitions > 8/24 h or\n\n               -  decrease in urgency urinary incontinence (UUI) or incontinence episodes / 24 h\n                  less than 50% or\n\n               -  decrease in urgency episodes / 24 h less than 50% or\n\n               -  decrease in number of micturitions / 24 h less than 20% or\n\n               -  not acceptible tolerability\n\n          -  Eligible to start Vesicare\u2122 5 or 10 mg according to Summary of Product\n             Characteristics (SmPC)\n\n        Exclusion Criteria:\n\n          -  History of stress incontinence\n\n          -  Active urinary tract infection (confirmed by positive urine analysis)\n\n          -  Symptoms suggestive of severe Bladder Outlet Obstruction (BOO) defined as  Peak\n             urinary flow rate (Qmax) < 10ml/sc and/or Postvoid residual urine volume (PVR) > 150\n             ml\n\n          -  Uncontrolled Diabetes Mellitus\n\n          -  History of drug and/or alcohol abuse at the time of enrolment\n\n          -  History of acute urinary retention, severe gastrointestinal obstruction (including\n             paralytic ileus or intestinal atony or toxic megacolon or severe ulcerative colitis),\n             myasthenia gravis, uncontrolled narrow glaucoma or swallow anterior chamber or deemed\n             to be at risk for these conditions.\n\n          -  Undergoing hemodialysis or has severe renal impairment or moderate hepatic impairment\n             and who are on treatment with a potent CYP3A4 inhibitor\n\n          -  Previous treatment with solifenacin\n\n          -  Likely to participate in another study during study period of 12 months from study\n             entry"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with OAB symptoms being treated by urologists in Czech Republic"
            }
        }, 
        "enrollment": {
            "#text": "2000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02087098", 
            "org_study_id": "VEST-001"
        }, 
        "intervention": {
            "arm_group_label": "Patients with residual OAB symptoms", 
            "description": "Patients with residual OAB symptoms (urge urinary incontinence, urgency, and frequency) after treatment with other antimuscarinics", 
            "intervention_name": "Solifenacin", 
            "intervention_type": "Drug", 
            "other_name": "Vesicare"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Muscarinic Antagonists", 
                "Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "overactive bladder", 
            "quality of life", 
            "solifenacin"
        ], 
        "lastchanged_date": "March 12, 2014", 
        "number_of_groups": "1", 
        "official_title": "Czech Observational Study to Evaluate Quality of Life in Patients Switched to Vesicare\u2122 (Solifenacin) From Other Antimuscarinics", 
        "overall_contact": {
            "email": "contact@nl.astellas.com", 
            "last_name": "Medical Affairs Europe", 
            "phone": "+44 (0)20 3379 8000"
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Europe B.V.", 
            "last_name": "Use Central Contact", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Czech Republic: State Institute for Drug Control", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from baseline of Over Active Bladder questionnaire Short Form (OAB-q SF) score", 
                "safety_issue": "No", 
                "time_frame": "baseline, month 6 and 12"
            }, 
            {
                "measure": "Change from baseline of Patient Assessment of Treatment Satisfaction (TS-VAS)", 
                "safety_issue": "No", 
                "time_frame": "baseline, month 6 and 12"
            }, 
            {
                "measure": "Change from baseline in EuroQol Group system (EQ-5D-5L) score", 
                "safety_issue": "No", 
                "time_frame": "baseline, month 6 and 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02087098"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in QoL according to previous antimuscarinic treatment and sex (assessed by: TS-VAS score, OAB-q SF score, EQ-5D-5L)", 
                "safety_issue": "No", 
                "time_frame": "baseline, month 1, 3, 6 and 12"
            }, 
            {
                "description": "Mean number of urgency episode per 24 hours, mean number of micturition per 24 hours, mean number of nocturia episodes per 24 hours, mean number of urge incontinence (UUI) episodes per week", 
                "measure": "Change from baseline in OAB symptoms assessed by micturition diary", 
                "safety_issue": "No", 
                "time_frame": "baseline, month 1, 3, 6 and 12"
            }, 
            {
                "measure": "Persistence to therapy (measured by proportion of Days Covered (PDC, threshold of 80 percent during the measurement period), median length of therapy (days))", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Occurence of adverse drug reaction", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Europe B.V.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}